Tirzepatide Research Compound (TR)

"Premium grade Tirzepatide validation."

Tirzepatide is a first-in-class dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, studied as a metabolic research compound. The SURMOUNT-1 phase 3 trial in adults with obesity documented dose-dependent reductions in body weight over 72 weeks (Jastreboff et al., N Engl J Med 2022, PMID 35658024). Tirzepatide research peptide is supplied lyophilized at ≥99% purity verified by HPLC, with identity confirmed by mass spectrometry and a batch-specific Certificate of Analysis (COA) included. Store lyophilized powder at −20 °C, protected from light and moisture. For laboratory research use only — not for human or animal consumption.